Claudette Klein, Ph.D.
Development of Zinc as a new chemotherapeutic option for the treatment of cancer.
Office: DRC, Room 415
Phone: (314) 977-9243
Ph.D., 1972, University of California, San Francisco
The primary goal of this research is to develop a new chemotherapeutic option for the treatment of cancer. We have chosen to develop Zn as a chemotherapeutic agent, based on our observations that Zn treatment of a variety of cancer cell lines results cell death. The rapidity with which cell death is induced is very attractive with respect to treatment protocols and is in dramatic contrast to the days-weeks required to achieve cell death with current chemotherapeutics. Importantly, Zn-mediated cell death is independent of the presence or absence of growth factors, is not limited to rapidly growing cells, and is independent of p53 status.
- Zinc is a potential therapeutic for chemoresistant ovarian cancer.
Bastow M, Kriedt CL, et al. J Exp Ther Oncol. (2011) 9(3):175-181.
- Zinc functions as a cytotoxic agent for prostate cancer cells independent of culture and growth conditions.
Kriedt CL, Baldassare J, et al. J Exp Ther Oncol. (2010) 8:287-295.